Driving CDMO Efficiency - The Power of Flexible Platforms and Digital Data Access

Gain an in-depth understanding of KBI Biopharma's flexible and innovative platform technologies, designed to drive next-generation bioprocessing efficiencies. 

Overview

Our experts discuss how the mammalian (SUREtechnology Platform™, powered by Selexis®) and microbial (PUREplatform™) End-to-End Cell Line Development solutions, combined with industry-leading analytical capabilities, accelerate the development, process characterization, and manufacturing of mAbs, multispecific Abs, ADCs, fusion proteins, and other recombinant therapeutic proteins.

We also provide insights into PROGRAMview™, our advanced digital collaboration platform, showcasing how it enhances data access and collaboration during process development. This platform supports faster, more informed decision-making, greater transparency, and improved communication, ultimately advancing bioprocess speed and quality.

Key topics:

• Explore how KBI Biopharma’s SUREtechnology Platform™ and PUREplatform™ expression systems streamline the development and manufacturing of complex biotherapeutics, including mAbs, multispecific Abs, ADCs, and fusion proteins.
• Learn how KBI Biopharma’s advanced analytics support process optimization, product characterization, and regulatory requirements more efficiently.
• Discover the features and benefits of PROGRAMview™, KBI Biopharma's digital collaboration platform, designed to enhance transparency and communication throughout process development.
  The session includes case studies, a demonstration of PROGRAMview™, and a Q&A with our experts.
  
  

Presenter

Erik Nordwald

Director, Head of Microbial Process Development

Shaunak Uplekar

Associate Director of Process Development

Marlee Paulson

PROGRAMview Product Owner

Let's Connect

Interested in learning more about KBI Biopharma? Contact us today.